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httpcense.Abstract Aim of the work: To assess the prevalence of sleep disturbance in female patients with
systemic lupus erythematosus (SLE) and to evaluate the correlation between sleep disturbance
and some disease parameters.
Patients and Methods: The Pittsburgh Sleep Quality Index (PSQI) was used to investigate the
sleeping habits of 30 female patients with SLE and of 30 healthy age and sex-matched controls.
Depressed mood was assessed using the Center for Epidemiological Studies Depression scale
(CES-D), functional disability was assessed with the Health Assessment Questionnaire (HAQ)
and pain severity was assessed using the visual analogue scale (VAS). Disease activity was measured
using the SLE disease activity index (SLEDAI). Disease severity and cumulative damage were mea-
sured using the Systemic Lupus International Collaborating Clinics/American College of Rheuma-
tology Damage (SLICC/ACR DI).
Results: The mean global scores for the PSQI were signiﬁcantly different between cases and con-
trols (8.47 ± 3.53 versus 5.10 ± 3.66, p= 0.000) indicating poor sleep quality for these patients
compared to healthy controls, and 76.7% (23 patients) were poor sleepers. Sleep disturbances were
correlated with disease duration (p= 0.001), functional disability (p= 0.001), SLEDAI
(p= 0.000), pain severity (p= 0.002), organ damage (p= 0.000) and depressed mood
(p= 0.000). However, with multivariate linear regression analysis SLEDAI and SLICC/ACR were
the only signiﬁcant predictors associated with higher level of PSQI.matology and Rehabilitation
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128 H.A. kotb et al.Conclusion: Sleep disturbances are prevalent among female SLE patients, with multiple factors
contributing to it, but disease activity and cumulative disease damage were the only predictors of
sleep quality. Assessment and management of sleep disturbances should be part of the routine care
of SLE patients.
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Sleep is a basic biological process possibly related to restor-
ative activity. Difﬁculty initiating sleep, maintaining sleep,
and/or early morning awakenings are all components of sleep
disturbance. Sleep disturbance is relatively common in women,
in older persons, and in individuals with fewer socioeconomic
resources [1,2]. Sleep disturbance is often seen in rheumatic
diseases and may contribute to the fatigue that is part of many
rheumatic conditions, including SLE. The prevalence of sleep
impairment and the factors contributing to sleep quality in pa-
tients with SLE remain poorly understood [3]. Poor sleep qual-
ity in association with depressed mood, disease activity,
prednisone use, lack of exercise and inﬂammatory cytokines
have been reported to contribute to decreased overall sleep
quality [4–7].
Sleep problems can complicate the management of SLE by
impairing patient’s quality of life [8], increasing fatigue [6],
triggering or worsening of depression [9], increasing work
absenteeism [10], and increasing healthcare costs [11]. More-
over and in particular relevance to SLE, experimental studies
inducing a partial night sleep deprivation typical to what pa-
tients with chronic medical diseases experience show alterna-
tions in immune function, which may negatively inﬂuence
inﬂammatory disease progression and cardiovascular risk
[12–14]. Also, symptoms of sleeping problems have been
repeatedly reported as being one of the under recognized needs
of SLE patients [15,16].
Therefore, the present study was conducted to assess the
prevalence of sleep disturbances among a group of Egyptian
female SLE patients and to ﬁnd its correlation to some disease
parameters.
2. Patients and methods
Thirty-eight consecutive female SLE patients fulﬁlling the
1982-revised criteria for the classiﬁcation of systemic lupus ery-
thematosus [17] were screened. They were followed up in the
outpatient clinic and the inpatient section of the Rheumatol-
ogy and Rehabilitation Department, Faculty of Medicine,
Cairo University. Eight patients were excluded from the study
for having one or more of the following exclusion criteria: cog-
nitive dysfunction, fulﬁllment of the ACR criteria for ﬁbromy-
algia [18] or other conditions that can lead to sleep
disturbances (obesity, sinusitis and obstructive sleep apnea).
Thirty age-matched healthy females served as controls. In-
formed consents were taken from the patients and the study
was approved by the local ethics committee.
Sociodemographic data, including age, education, occupa-
tion, disease duration and marital status, were recorded. Full
history taking, thorough clinical examination and laboratory
investigations were done. Prescribed medications at the time
of inclusion in the study were also recorded.The disease activity level was evaluated with the Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI) [19].
A mini mental status examination (MMSE) was performed
in all patients to rule out cognitive dysfunction, especially in
those with central nervous system (CNS) involvement [20]. It
is a brief 30-point questionnaire test that is used to screen
for cognitive impairment. In about ten minutes it samples
functions including memory and orientation. Any score great-
er than or equal to 25 points (out of 30) indicates a normal
cognition.
Systemic lupus cumulative damage was measured using the
Systemic Lupus International Collaborating Clinics/American
College of Rheumatology Damage Index (SLICC/ACR DI)
[21]. Depressed mood was assessed using the Center for Epide-
miological Studies Depression scale (CES-D). CES-D is a self-
reported 20-item scale. Each of the items is rated on a 4-point
scale, with a minimum score of zero and a maximum score of
60. It is designed to assess depressive symptoms in non-psychi-
atric populations. Scores of 16 or greater on the CES-D are
interpreted as being suggestive of clinically signiﬁcant depres-
sion [22].
Functional disability was measured by the Health Assess-
ment Questionnaire (HAQ) and pain severity was assessed
by the HAQ 15 cm VAS, with 0 denoting no pain and 100 indi-
cating very severe pain. Pain scores were then rescaled from 0
to 3, using pain severity coding translations, with 0 represent-
ing no pain and three severe pain [23].
Sleep quality was assessed using the Pittsburgh Sleep Qual-
ity Index (PSQI). The PSQI is a self-report measure that as-
sesses sleep quality and disturbances over a 1-month interval.
It includes 19 items, generating seven component scores: sub-
jective sleep quality, sleep latency, sleep duration, habitual
sleep efﬁciency, sleep disturbances, use of sleeping medication,
and daytime dysfunction. A global score is obtained by sum-
ming the seven component scores and has a possible range
of 0–21 points, a higher score indicating poorer sleep quality.
The scale has good psychometric properties with a global score
P6 yielding a diagnostic sensitivity of 89.6% and speciﬁcity of
86.5% in differentiating good and poor sleepers [24].
Statistical Package for Social Science (SPSS) program ver-
sion 15 was used for analysis of data. Data were summarized
as mean ± SD. Mann–Whitney test was used for comparing
and analysis of two quantitative data. Spearman’s correlation
was used for detection of the relation between two variables. A
series of hierarchical multiple regression analyses were per-
formed to test the importance of disease-related and psychoso-
cial factors to sleep quality after controlling for demographic
factors [25]. Each hierarchical regression analysis computed
whether the variance explained by the speciﬁc set contributed
signiﬁcantly to the total variance in sleep quality after control-
ling for the demographic set. A full model analysis was then
computed with all the variables entered simultaneously into
the model to determine the relative contributions of these
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cant if < 0.05.
3. Results
The demographic and clinical characteristics of the SLE pa-
tients and controls are shown in Table 1. The mean SLEDAI
score was 12.17 ± 5.41; 13 patients (43.3%) had mild disease
activity, 14 (46.7%) had moderate and 3 (10%) had severe dis-
ease activity. All patients were on corticosteroids, 12 (40%)
were taking <7.5 mg/day and 18 (60%) >7.5 mg/day of pred-
nisolone while 70% of them did not use any sleep medication.
The mean SLICC/ACR DI score was 0.97 ± 0.93. The mean
HAQ-DI was 1.34 ± 0.95 and the pain-VAS was
1.37 ± 0.58. The mean score of the CES-D was 20.8 ± 6.98,
with 22 patients (73.3%) scoring at or above the standard cut-
off score (P16) for clinically signiﬁcant levels of depression.
Patients with SLE had higher mean PSQI scores, indicating
poorer sleep quality compared to healthy controls (8.47 ± 3.53
versus 5.1 ± 3.66, p= 0.000). Twenty-three (76.7%) patients
were poor sleepers with a PSQI global score of P6 compared
to nine of the control group (30%), p= 0.000. There were sta-
tistical signiﬁcant differences between patients and control
group (p< 0.05) in most of the component scores of PSQITable 1 Demographic and clinical characteristics of the SLE
patients and controls.
Characteristic mean ± SD Controls
(n= 30)
SLE patients
(n= 30)
Age in years 26.57 ± 6.82 26.17 ± 6.75
Disease duration in years – 4.12 ± 2.46
Education in years 13.67 ± 2.31 7.60 ± 6.15
Unmarried: married: divorced:
widow
13:15:1:1 11:17:1:1
CES-D 13.13 ± 2.83 20.80 ± 6.98
SLEDAI – 12.17 ± 5.41
SLICC/ACR – 0.97 ± 0.93
HAQ-pain – 1.37 ± 0.58
HAQ-DI – 1.34 ± 0.95
CES-D= Center for Epidemiological Studies Depression scale,
SLEDAI = Systemic Lupus Erythematosus Disease Activity
Index, SLICC/ACR= Systemic Lupus International Collaborat-
ing Clinics/American College of Rheumatology Damage Index,
HAQ-DI = Health Assessment Questionnaire Disability Index,
HAQ-pain = Pain index of the HAQ.
Table 2 Comparison of the components of PSQI in SLE patients a
PSQI components mean ± SD SLE patients (n= 30
Subjective sleep quality 1.40 ± 1.07
Sleep latency 2.03 ± 0.89
Sleep duration 0.70 ± 0.99
Habitual sleep eﬃciency 1.03 ± 0.89
Sleep disturbance 1.47 ± 0.63
Use of sleep medication 0.60 ± 1.07
Daytime dysfunction 1.23 ± 0.77
Global PSQI 8.47 ± 3.53
PSQI = The Pittsburgh Sleep Quality Index.
* Signiﬁcant.except sleep latency, sleep duration and use of sleep medica-
tions, which showed no statistically signiﬁcant difference be-
tween both groups (Table 2).
Spearman’s coefﬁcients were done to identify the correlates
of sleep quality in SLE patients. As shown in Table 3, disease
duration (p= 0.001), disease activity (p= 0.000), functional
disability (p= 0.001), organ damage index (p= 0.000), pain
severity (p= 0.002) and depressed mood (p= 0.000) were sig-
niﬁcantly correlated with poorer sleep quality. The correlation
of the PSQI with the SLEDAI and SLICC is graphically pre-
sented in ﬁgs. 1 and 2. The dose of corticosteroids did not sig-
niﬁcantly correlate with poorer sleep quality (p= 0.290). The
SLEDAI signiﬁcantly correlated with the CES-D (r= 0.713,
p= 0.000) and with the HAQ-DI (r= 0.713, p= 0.000). Fur-
thermore, the SLICC/ACR DI signiﬁcantly correlated with
SLEDAI (r= 0.510, p= 0.004), CES-D (r= 0.446,
p= 0.014) and HAQ-DI (r= 0.527, p= 0.003).
Among SLE patients, when demographic and clinical
parameters of good (PSQI <6) and poor (PSQI P6) sleepers
were compared; disease duration (2 ± 1.55 versus 4.76 ± 2.33,
p= 0.006), disease activity (6.29 ± 2.14 versus 13.96 ± 4.7,
p= 0.001), functional disability (0.34 ± 0.38 versus
1.3 ± 0.73, p= 0.003), pain severity (0.73 ± 0.54 versus
1.57 ± 0.43, p= 0.003) depressed mood (12.14 ± 2.27 versus
23.43 ± 5.64, p= 0.000) and damage index (0.14 ± 0.38 ver-
sus 1.22 ± 0.90, p= 0.006) were found to be signiﬁcantly dif-
ferent (Table 4).
The results of the hierarchical multiple regression analyses
are shown in Table 5. Model 1 (demographic model) tests
the contribution of demographic variables (age and education
years) to disturbed sleep and was not found to be statistically
signiﬁcant (R2 = 0.073). Model 2 (disease-related model) tests
the contributions of disease activity, disease severity and dam-
age, functional disability and pain severity to poor sleep qual-
ity after controlling for the demographic variables. The
addition of disease-related variables resulted in a signiﬁcant in-
crease in the R2 value (R2 = 0.658). In this disease-related
model, disease activity (p= 0.027), contributed signiﬁcantly
to poor sleep quality. Model 3 (psychosocial model) describes
the extent to which depression contributes to sleep disturbance
after controlling for the demographic variables. Inclusion of
depressed mood (CES-D) also signiﬁcantly added to the demo-
graphic set (R2 = 0.474) and contributed signiﬁcantly
(p= 0.000).
Models 1–3 are the results of hierarchical regression analy-
ses, which are done to determine the importance of predictor
variables. Model 4 is the standard regression analysis wherend control.
) Controls (n= 30) p value
0.70 ± 1.09 0.016*
1.47 ± 0.94 0.141
1.03 ± 0.96 0.162
0.53 ± 0.78 0.041*
0.93 ± 0.37 0.003*
0.07 ± 0.25 0.083
0.37 ± 0.56 0.000*
5.10 ± 3.66 0.000*
Table 3 Correlation of the sleep quality with demographic,
clinical and psychosocial variables.
Variables r p
Age 0.228 0.225
Disease duration 0.558 0.001*
Years of education 0.253 0.177
CES-D 0.681 0.000*
HAQ-DI 0.568 0.001*
HAQ-pain 0.543 0.002*
SLEDAI 0.695 0.000*
SLICC/ACR 0.658 0.000*
Corticosteroid dose 0.200 0.290
CES-D= Center for Epidemiological Studies Depression scale,
SLEDAI = Systemic Lupus Erythematosus Disease Activity
Index, SLICC/ACR= Systemic Lupus International Collaborat-
ing Clinics/American College of Rheumatology Damage Index,
HAQ-DI = Health Assessment Questionnaire Disability Index,
HAQ-pain = Pain index of the HAQ.
* Signiﬁcant.
Figure 1 The relationship between sleep disturbance (PSQI) and
disease activity (SLEDAI).
Figure 2 The relationship between sleep disturbance (PSQI) and
disease severity and cumulative damage index (SLICC/ACR-DI).
Table 4 Comparison between good and poor sleepers in SLE
patients.
Variables PSQI
Mean ± SD <6 (n= 7) >6 (n= 23) p value
Disease duration 2 ± 1.55 4.76 ± 2.33 0.006*
Years of education 11.86 ± 3.8 6.30 ± 6.20 0.05
CES-D 12.14 ± 2.27 23.43 ± 5.64 0.000*
HAQ-DI 0.4 ± 0.5 1.6 ± 0.9 0.003*
HAQ-pain 0.73 ± 0. 54 1.57 ± 0.43 0.003*
SLEDAI 6.29 ± 2.14 13.96 ± 4.79 0.001*
SLICC/ACR 0.14 ± 0.38 1.22 ± 0.90 0.006*
PSQI = The Pittsburgh Sleep Quality Index, CES-D= Center for
Epidemiological Studies Depression scale, SLEDAI = Systemic
Lupus Erythematosus Disease Activity Index, SLICC/
ACR= Systemic Lupus International Collaborating Clinics/
American College of Rheumatology Damage Index, HAQ-
DI = Health Assessment Questionnaire Disability Index, HAQ-
pain = Pain index of the HAQ.
* Signiﬁcant.
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their relative contributions to sleep quality. This model takes
into account the interrelations between predictor variables as
well as the effects of predictor variables on the outcome vari-
able (PSQI). In the ﬁnal full model (standard multiple regres-
sion analysis), only disease activity (p= 0.002) and organ
damage index (p= 0.007) were the signiﬁcant determinants
of sleep quality.
4. Discussion
Patients with SLE reported signiﬁcantly greater sleep distur-
bance in comparison with control subjects with their PSQI
scores indicating clinical sleep impairment and 76.7% of them
had poor sleep quality. Similarly, Greenwood and colleagues
reported a prevalence of 80.5% [26] while other studies
[3,6,27] reported a lower prevalence using PSQI in their co-
horts of SLE patents (52%, 60%, and 62% respectively). In
these three studies, the patient sample was recruited from out-
patient clinics with no inpatients included, which could explain
the higher prevalence of sleep disturbances in the present
study.
Patients with SLE had poor sleep quality as compared to the
control group with higher mean global PSQI score. Among the
seven components of PSQI, the most prominent component of
sleep disturbance was daytime dysfunction. Despite the high
prevalence of sleep complaints among patients, 70% of them
did not use any sleep medication, which indicates underestima-
tion of the problem among this patient population.
In the present study, poor sleep was associated with longer
disease duration and higher SLEDAI. Valencia-Flores et al., in
their small cohort of SLE patients (n = 14), found that those
with active disease reported signiﬁcantly poorer sleep efﬁ-
ciency, longer stage 1 sleep, shorter slow-wave sleep and more
number of arousals compared to patients with inactive disease
[4]. In another study, it has been found that sleep complaints
were more frequently reported by SLE patients who had more
active disease, especially those with central nervous system
involvements, compared to those with less active disease [7].
Table 5 Regression models predicting sleep quality in SLE patients.
Predictors Model 1 Model 2 Model 3 Model 4
Beta p Beta p Beta p Beta p
Age 0.061 0.619 0.073 0.451 0.028 0.765 0.061 0.520
Education (years) 0.104 0.444 0.030 0.781 0.036 0.733 0.013 0.901
Disease duration 0.121 0.689 0.006 0.983
SLICC/ACR 1.407 0.104 1.357 0.007
SLEDAI 0.305 0.027 0.191 0.002
HAQ-DI 0.039 0.688 0.042 0.657
VAS 0.791 0.521 1.139 0.357
Prednisone use 0.008 0.166 0.006 0.316
CES-D 0.331 0.000 0.144 0.165
R2 0.073 0.658 0.474 0.690
Adjusted R2 0.004 0.528 0.413 0.551
CES-D= Center for Epidemiological Studies Depression scale, SLEDAI = Systemic Lupus Erythematosus Disease Activity Index, SLICC/
ACR= Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, HAQ-DI = Health Assess-
ment Questionnaire Disability Index, HAQ-pain = Pain index of the HAQ. Bold values are signiﬁcant.
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sleep quality in SLE has been reported [6]. Da Costa and col-
leagues, when using bivariate analyses, also found an associa-
tion between disease activity and sleep quality assessed with
the PSQI [3]. However, this association did not remain signif-
icant in the multivariate analysis, suggesting that the relation-
ship between sleep and disease activity may be weak and
nonlinear. In our study as well as that of Chandrasekhara
and coworkers, [27] this association remained signiﬁcant in
the multivariate analysis. In autoimmune diseases, the elevated
levels of proinﬂammatory cytokines may inﬂuence daytime
sleepiness and disrupt nocturnal sleep [28]. This pathway re-
mains to be explored in SLE. Importantly the relationship be-
tween cytokines and sleep has been found to be bidirectional,
with altered sleep also inﬂuencing cytokine levels in other pop-
ulations [29–31].
Our study showed also a signiﬁcant correlation between
poor sleep quality, functional disability as measured by
HAQ-DI and depression as assessed by CES-D. However un-
like disease activity, these associations did not remain signiﬁ-
cant in the ﬁnal full model of standard multiple regression
analysis. This could be explained by the signiﬁcant correlation
found between disease activity (by SLEDAI), presence of
depressive symptoms (by CES-D) and functional disability
(by HAQ-DI).
The relationship between disease activity, functional dis-
ability and depression has been previously documented. Dis-
ease activity is a potential risk factor for the presence and
severity of major depression in patients with SLE [32]. On
the other hand, depression can in turn contribute to increased
disease activity and may be an important cause of medication
adherence problems that contributes to higher disease activity
[33]. Depression severity has also been shown to correlate with
functional disability [34]. In addition to depression, disease
activity has been documented as contributing to functional dis-
ability in patients with SLE [35]. Again, functional disability
signiﬁcantly contributes to depressed mood [36]. Finally, the
role of depression in producing sleep disturbance is also well
documented [3].
The relationship between pain intensity and sleep problems
has been ﬁrmly documented in some rheumatic diseases as
rheumatoid arthritis and ﬁbromyalgia [37]. In our study, therewas a positive correlation between PSQI score and pain sever-
ity as measured by VAS. Among SLE patients, Tench and
associates [6] reported a moderate correlation between pain
and poor sleep quality. Another study found that SLE patients
reported signiﬁcantly more pain when trying to fall asleep and
during the night compared with age-matched controls [7].
Using multivariate analyses, a very weak relationship between
pain and sleep disturbance was found [3,4].
In the present study, despite the low organ damage score
SLICC/ACR-DI, it signiﬁcantly correlated with sleep distur-
bances and this association remained signiﬁcant in the multi-
variate analysis as an independent determinant of poor sleep
quality in SLE patients. The statistically signiﬁcant correlation
between SLICC/ACR DI and the SLEDAI, the CES-D and
the HAQ-DI in the current study could explain this ﬁnding.
Corticosteroids, at least in high doses, may give rise to sleep
problems and some psychiatric symptoms [37]. However, our
study as well as some other previous studies have not shown
a relationship between use and dose of corticosteroids and
sleep disturbance in SLE [4,6,7].
In conclusion, our study shows a high prevalence of sleep
disturbances among studied Egyptian female SLE patients.
Several factors contribute to poor sleep quality in these pa-
tients including disease activity, functional disability, depres-
sion and cumulative damage. However, disease activity and
cumulative disease damage were the only predictors of sleep
quality. Assessment and management of sleep problems should
be part of the management of patients with SLE.
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